ClinicalTrials.gg
Not yet recruitingNCT05864885Updated May 18, 2023

Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia

A Phase 1 interventional study of Minoxidil in Androgenetic Alopecia, sponsored by Aneira Pharma, Inc.. Not yet recruiting. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-18.

Sponsored by Aneira Pharma, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2023, 3 years 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing minoxidil in Alopecia — 10 open to participants now, 12 under way, 3 of them phase 3. Minoxidil · Alopecia.

Planned enrollment
26th of 31
14 · median 60
Started
2023
with 4 others
Phase 1
4 of 31
3 open now
Primary completion
2023-07
later than 0 of 11 live
Registered
19th of 31
by date
Lead sponsor
1 of 31
Aneira Pharma, Inc.

Among the 31 studies testing minoxidil in Alopecia, this one is the 26th largest by planned enrollment, is one of 5 that started in 2023, is one of 4 in phase 1, reaches primary completion later than 0 of the 11 other live ones, and was the 19th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 128 are open to participants now.

Browse Alopecia studies →

Open to participants now

10 of the 31 studies testing minoxidil in Alopecia are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About minoxidil

Minoxidil: first FDA approval 1979 (LONITEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 76 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 48 (63%) stop at 75 or younger; 10 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing minoxidil in Alopecia, or all of them as a file.
02

Study summary

This study will be a single center, open-label study of a single concentration of ANR- 001.1. The solution will be applied to the scalp of 14 male subjects by study staff once daily for 7 days.

Read the detailed description

At screening, subjects will sign informed consent and inclusion and exclusion will be reviewed for each subject. Screening data will include demographics, medical history, concomitant medications, physical examination, weight, O2 sat, vital signs laboratory evaluation (CMP, CBC, UA), and ECG.

At Day 1, a physical exam, weight, O2 sat, vital signs (including BP, pulse, respiratory rate and temperature) and review of concomitant medications will be performed, and admission criteria reviewed.

If criteria are met, the study staff will administer the first dose of study medication to the area of hair loss on the scalp (8 cm x 6 cm). If there is no hair loss the dose will be administered to the crown of the head (8 cm x 6 cm). The study staff will continue to administer the study medication to the same area of the scalp of the subject, once daily for Study Days 1, 2, 3, 4, 5, 6, and 7. Daily subject visits will include vital signs, review of adverse events and concomitant medications. PK draws and ECGs will take place at Study Days 1, 2, 7 and 8, following the first dose and the last doses, respectively.

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Males between age 18 to 65 years, in general good health. Good health is defined as a subject without any active diseases. Not included in active diseases are:

  • Migraines
  • Non-hospitalized depression o Asthma
  • Cholecystectomy
  • Gilbert's syndrome

    • Clinical diagnosis of AGA with grade II to VI hair loss on Norwood Hamilton Classification System
    • Subjects of any Fitzpatrick skin type or race provided their degree of skin pigmentation does not, in the Investigator's opinion, interfere with study assessments.
    • No known allergy to ANR-001.1 or any of its components.
    • Subject is willing to avoid extensive sun exposure, phototherapy, or use of tanning salon for the duration of the study.

Exclusion criteria

Exclusion Criteria:

If subjects have a outside of the range of 18-35kg/m2

  • Subjects using a minoxidil product (e.g., Rogaine or generic Rogaine) or a latanoprost product (e.g., Xalatan or generic Xalatan) within 30 days of the start of Day 1 of the study.
  • Subjects whose vital signs, , safety labs or physical exam results are in the opinion of the investigator.
  • Subjects have a skin condition that, in the Investigators opinion, could interfere with study assessment or put the subject at undue risk by study participation.
  • Subjects with an active or recent (within 30 days before Day 1) disease or infection, or chronic dermatological condition (eczema, psoriasis, infection, etc.).
  • Subjects with known or suspected or allergic reaction to any of the active or inactive components of the test treatment.
  • Current enrollment in any other medication (drug) study within the 4 weeks prior to study initiation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Primary safety and pharmacokinetic data

    To obtain primary safety and pharmacokinetic data on the ANR- 001.1 when applied topically, once daily, for 7 days to the scalp

    Drug: Minoxidil

Interventions

  • Topical formulation applied once a day.

    Also known as: Latanoprost

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic data: Cmax

    Individual and mean maximum plasma concentration (Cmax)

    Time frame: 7 days

  2. Pharmacokinetic data: tmax

    Individual and mean tmax

    Time frame: 7 days

  3. Pharmacokinetic data: Half-life (t1/2)

    Individual and mean half-life (t1/2)

    Time frame: 7 days

  4. Pharmacokinetic data: AUC

    Individual and mean area under the concentration-time curve calculated from time zero to the last observable concentration at time t (AUC0-t)

    Time frame: 7 days

  5. Pharmacokinetic data: Drug clearance

    Individual and mean apparent clearance of drug from plasma

    Time frame: 7 days

  6. Safety : Skin TEAEs

    Incidence of treatment-emergent adverse events related to skin irritation at the administration site

    Time frame: 7 days

  7. Safety: Systemic TEAEs

    Incident of systemic treatment-emergent adverse events

    Time frame: 7 days

  8. Safety: Evaluation of QTs Interval Prolongation

    Change from baseline in the frequency of marked QTc prolongation at each visit where ECG is performed

    Time frame: 7 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2023; primary completion for Jul 2023, 1 month later.

Of 33 phase 1 interventional studies under Alopecia, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 57. This study's planned 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2023
First posted
May 18, 2023
StartEst.
Jun 9, 2023
Primary completionEst.
Jul 17, 2023
CompletionEst.
Jul 17, 2023
Last update
May 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05864885
Lead sponsor
Aneira Pharma, Inc.
Collaborators
DataPharm Australia, CMAX Clinical Research, Agilex Australia
Responsible party
Sponsor
First posted
May 18, 2023
Start date
Jun 9, 2023 (estimated)
Primary completion
Jul 17, 2023 (estimated)
Completion
Jul 17, 2023 (estimated)
Last update
May 18, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Minoxidil

Start the discussion